StockNow
Log in
U.S. Markets

Boston Scientific (BSX) now expects a more pressured second half, cutting FY26 organic revenue growth guidance to 5%-6% and adjusted EPS guidance to USD 3.28-3.32, implying 7%-8% growth, remarks via earnings call

StockNow breaking-news AI analysis

Boston Scientific cut FY26 guidance due to softening Watchman device demand despite beating Q2 estimates. Management launched a restructuring plan to offset second-half pressures and optimize costs.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)